Updated: 04/2025

**Request for Prior Authorization for Duvyzat (givinostat)** Website Form – www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158

All requests for Duvyzat (givinostat) require a Prior Authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

## **Duvyzat (givinostat) Prior Authorization Criteria:**

Coverage may be provided with a diagnosis of Duchenne muscular dystrophy (DMD) and all of the following criteria is met:

- A confirmed diagnosis of DMD by submission of lab testing demonstrating mutation of the dystrophin gene
- The member must be ambulatory
- Is age-appropriate according to FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature
- The member must have had baseline platelet counts and triglyceride lab work completed
- Member does not have any of the following clinically significant abnormal lab values:
  - $\circ$  QT c interval is > 500 ms or the change from baseline is > 60 ms
  - o platelets count  $\leq 150 \times 10^{9}$ L.
  - o white blood cells  $\leq 2.0 \times 10^{9}$ L
  - o hemoglobin  $\leq 8.0 \text{ g/dL}$
  - o Fasting triglycerides >300 mg/dL
- The member will receive concurrent corticosteroids unless contraindicated or intolerant
- Must be prescribed by or in consultation with a neurologist who has experience in the treatment and ongoing management of DMD
- Member has documentation of a baseline evaluation, including a standardized assessment of motor function such as one of the following:
  - o 4 Standard Stairs (4SC) Climb
  - o Rise From Floor
  - o Total North Star Ambulatory Assessment (NSAA)
  - Six-minute walk test (6MWT)
- The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines
- **Initial Duration of Approval:** 6 months
- **Reauthorization criteria:** 
  - o The member has documentation of an annual evaluation, including laboratory values since starting treatment, by a neurologist who has experience in the treatment and management of DMD
  - o The member is receiving concurrent corticosteroids unless contraindicated or intolerant
  - o Documentation demonstrating the member is stable or shows clinically significant improvement in DMD symptoms, as demonstrated by stable or improved functional

abilities test results compared to baseline or previous functional abilities test whichever is most recent (4SC, Rise from Floor, NSAA, 6MWT.)

Updated: 04/2025

**Reauthorization Duration of Approval:** 12 months

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peerreviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.

Drugs are authorized in generic form unless the branded product is on the preferred drug list or the prescriber has indicated in writing that the branded product is medically necessary. If only the branded product is on the preferred drug list, the generic form will be considered non-preferred and shall not require the prescriber to indicate in writing that the branded product is medically necessary.



Updated: 04/2025 DMMA Approved: 05/2025

## **DUVYZAT (GIVINOSTAT)** PRIOR AUTHORIZATION FORM- PAGE 1 of 2

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Highmark Health Options Pharmacy Services. FAX: (855) 476-4158

If needed, you may call to speak to a Pharmacy Services Representative. **PHONE**: (844) 325-6251 Monday through Friday 8:00am to 7:00pm PROVIDER INFORMATION Requesting Provider: NPI: Provider Specialty: Office Contact: Office Address: Office Phone: Office Fax: MEMBER INFORMATION Member Name: DOB: Member ID: Member weight: Height REQUESTED DRUG INFORMATION Medication: Strength: Refills: Directions: Quantity: Is the member currently receiving requested medication? 

Yes No Date Medication Initiated: Is this medication being used for a chronic or long-term condition for which the medication may be necessary for the life of the patient? Yes No **BILLING INFORMATION** This medication will be billed:  $\square$  at a pharmacy **OR** medically (if medically please provide a JCODE: Provider's office Member's home Other Place of Service: Hospital PLACE OF SERVICE INFORMATION NPI: Name: Address: Phone: **MEDICAL HISTORY (Complete for ALL requests)** Diagnosis: Duchenne muscular dystrophy (DMD) Other: Was the diagnosis confirmed with lab testing demonstrating mutation of the dystrophin gene? Yes No Is the member ambulatory? \( \subseteq \text{Yes} \) No Has the member had baseline platelet counts and triglyceride lab work completed? Yes No Does the member have any of the following clinically significant abnormal lab values? (check all that apply) QTc interval is > 500 ms or the change from baseline is > 60 ms  $\circ$  Platelets count < 150 x 10<sup>9</sup>/L. ○ White blood cells  $\leq 2.0 \times 10^{9}$ L o Hemoglobin ≤8.0 g/dL Fasting triglycerides >300 mg/dL Is the member taking concurrent corticosteroids unless contraindicated or intolerant? 

Yes 

No Is there documentation the member has had a baseline evaluation including a standardized assessment of motor function such as one of the following (select those that apply): o 4 Standard Stairs (4SC) Climb Rise From Floor Total North Star Ambulatory Assessment (NSAA) Six-minute walk test (6MWT) REAUTHORIZATION Does the member have documentation of an annual evaluation, including laboratory values since starting treatment, by a neurologist who has experience in the treatment and management of DMD? \(\subseteq\) Yes \(\subseteq\) No Is the member receiving concurrent corticosteroids unless contraindicated or intolerant? \( \subseteq \text{Yes} \) No Is there documentation demonstrating the member is stable or shows clinically significant improvement in DMD symptoms, as demonstrated by stable or improved functional abilities test results compared to baseline or previous functional abilities test whichever is most recent (4SC, Rise from Floor, NSAA, 6MWT.)? Please submit documentation. \( \subseteq \text{Yes} \quad \subseteq \text{No} \)



Updated: 04/2025 **HEALTH OPTIONS** DMMA Approved: 05/2025 DUVYZAT (GIVINOSTAT)

## PRIOR AUTHORIZATION FORM (CONTINUED) – PAGE 2 OF 2

as applicable to Highmark Health Options Pharmacy Services. FAX: (855) 476-4158

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation If needed, you may call to speak to a Pharmacy Services Representative. **PHONE**: (844) 325-6251 Mon – Fri 8 am to 7 pm MEMBER INFORMATION DOB: Member Name: Member ID: Height: Member weight: **CURRENT or PREVIOUS THERAPY** Status (Discontinued & Why/Current) **Medication Name** Strength/ Frequency **Dates of Therapy** SUPPORTING INFORMATION or CLINICAL RATIONALE **Prescribing Provider Signature** Date



Updated: 04/2025 DMMA Approved: 05/2025